The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•20 March 2026•

1 min read

SELLAS Stock Surges 346% as Cancer Vaccine Trial Nears Critical Milestone

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1SELLAS Life Sciences Group (SLS) stock has surged 346% over the past year.

2The company is nearing a critical inflection point in its Phase 3 REGAL trial for a cancer vaccine, with only 8 deaths remaining to reach the clinical endpoint.

Version History

4 additional sources confirmed this story

SELLAS Life Sciences Group (SLS) has witnessed a remarkable 346% surge in its stock price over the past year, driven by investor optimism regarding its medical research. The company is currently nearing a critical inflection point in its Phase 3 REGAL trial for a promising cancer vaccine. Current data indicates that only 8 events remain to reach the clinical endpoint required to trigger the final analysis of the trial. As a late-stage clinical biopharmaceutical company, SELLAS is heavily focused on developing innovative immunotherapies for various cancer types. Investors are closely monitoring the situation, as the binary nature of clinical trial results often leads to significant volatility in the biotech sector. The successful completion of the REGAL trial could validate the company's lead candidate and provide a substantial boost to its market valuation.